NCT07214961View on ClinicalTrials.gov

Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2033

Study Completion Date

September 30, 2033

Conditions
Prostate Cancer (CRPC)Metastatic Castrate Resistant Prostate Cancer (mCRPC)
Interventions
DRUG

AB001

Pb-212 PSMA targeted alpha radioligand therapy

Trial Locations (4)

49503

BAMF Health, Grand Rapids

63110

Washington University, St Louis

68130

XCancer, 17607 Gold Plaza, Omaha

08540

United Theranostics, Princeton

Sponsors

Lead Sponsor

ARTBIO Inc.
All Listed Sponsors
lead

ARTBIO Inc.

INDUSTRY

NCT07214961 - Study of Alpha Radioligand Therapy AB001 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Biotech Hunter | Biotech Hunter